Scandion Oncology: Announces cSEK60m rights issue - Redeye

Redeye comments on Scandion Oncology announcing a cSEK60m rights issue. A capital raise aligned with our expectations, considering our burn rate projections and Scandion’s cash position at the end of Q4 2023. As Scandion has not yet announced final terms, we place our estimates and valuation under review.

Länk till analysen i sin helhet: https://www.redeye.se/research/996387/scandion-oncology-announces-csek60m-rights-issue?utm_source=finwire&utm_medium=RSS